VENLAFAXINE KRKA L.P. 37.5 mg, extended-release capsule 30 capsules
Active ingredients: Venlafaxine hydrochloride, Venlafaxine
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only
Extended-release capsule30 capsulesorale
Supply disruption
Package details
Original BDPM fields are shown in French.
- Official name
- VENLAFAXINE KRKA L.P. 37,5 mg, gélule à libération prolongée
- Pharmaceutical form
- gélule à libération prolongée
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) aluminium PVC PVDC de 30 gélule(s)
- Marketing authorisation holder
- KRKA (SLOVENIE)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 21 Feb 2013
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61556809CIP74961096CIP133400949610969Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE VENLAFAXINEgélule | 42,43 mg · une gélule | SA |
| VENLAFAXINEgélule | 37,5 mg · une gélule | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.